Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Hibiscus vs MitoQ: Hibiscus has the stronger overall evidence (6 vs 5/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Hibiscus wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (1)
Outcomes where both Hibiscus and MitoQ have evidence — compare verdict strength side-by-side.
250–450 mg standardized extract OR 1.25–2.5 g dried calyx per serving (as tea)
With meals, 2–3 times daily, Morning and afternoon preferred
Standardized extract capsule (anthocyanins ≥10%)
10-20mg daily
Morning
Oral capsule (mitoquinol mesylate, 10-20 mg)
and 1 more not shown
4–6 weeks
6–8 weeks
Acute to 2 weeks
4–8 weeks
Acute to 6 weeks
4 weeks
12 months
3 weeks
Efficacy and safety of Hibiscus sabdariffa in cardiometabolic health: An overview of reviews and updated dose-response meta-analysis.
Complementary therapies in medicine (2025) · Meta analysis · n=1797
Overview of systematic reviews and updated dose-response meta-analysis confirms cardiometabolic benefits of Hibiscus sabdariffa
A systematic review and meta-analysis of the effects of Hibiscus sabdariffa on blood pressure and cardiometabolic markers.
Nutrition reviews (2022) · Meta analysis
Hibiscus significantly reduced systolic BP by −7.10 mmHg (95%CI −13.00 to −1.20) versus placebo
Efficacy of Hibiscus sabdariffa on Reducing Blood Pressure in Patients With Mild-to-Moderate Hypertension: A Systematic Review and Meta-Analysis of Published Randomized Controlled Trials.
Journal of cardiovascular pharmacology (2022) · Meta analysis · n=1205
13 RCTs (1205 participants) analyzed; hibiscus significantly reduced SBP by −6.67 mmHg and DBP by −4.35 mmHg vs placebo
Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults.
Hypertension (Dallas, Tex. : 1979) (2018) · Rct · n=20
Randomized, placebo-controlled, double-blind crossover trial in 20 healthy older adults (60-79 yr) with impaired endothelial function
A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society (2010) · Rct · n=128
PROTECT: multicenter double-blind RCT of 128 newly diagnosed, untreated Parkinson's patients over 12 months
The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients.
Liver international : official journal of the International Association for the Study of the Liver (2010) · Rct · n=30
Phase-II RCT: 30 chronic hepatitis-C patients randomized to mitoquinone (40 or 80 mg) or placebo once daily for 28 days
Hibiscus has a higher evidence score (6/10 vs 5/10) and wins in 2 of 3 categories.
For support heart health, Hibiscus has a higher relevance score (75 vs 60).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.